ClinicalThought™
Interact with experts and peers.

Recent Posts

10 of 86 Shown
  • The Imperative for Women-Initiated HIV Prevention Technologies

    Quarraisha Abdool Karim PhD - 7/8/2016 1 comment / Last Comment: 7/11/2016
    Professor Quarraisha Abdool Karim, PhD, introduces her take on one of the key challenges for women at risk of HIV infection and evolving strategies for prevention. At an upcoming symposium in Durban, Catherine Hankins, MD, PhD, FRCPC, CM, and a multidisciplinary panel of experts will continue this discussion by providing their perspectives on 3 global challenges to treatment and prevention of HIV in women.
  • Switch Strategies in Virologically Suppressed Patients: My Take on New Data From Recent Scientific Meetings

    Anton L. Pozniak MD, FRCP - 1/22/2016 10 comments / Last Comment: 3/8/2016
    Several recent studies have highlighted new approaches to ART switching. Some may expand our options for optimizing long-term virologic suppression in our patients; each should be scrutinized carefully before incorporating into practice.
  • Selecting First-line Antiretroviral Therapy in Older Patients: New Data, New Options, Key Considerations

    Giovanni Guaraldi MD - 12/16/2015 2 comments / Last Comment: 2/10/2016
    The management of ART in patients aging with HIV requires clinicians to maintain a detailed knowledge of physical and psychological patient health in order to tailor the most appropriate ART regimen.
  • ART in Older Patients: How I Manage Drug–Drug Interactions With Concomitant Medications

    Anton L. Pozniak MD, FRCP - 10/20/2015 16 comments / Last Comment: 5/10/2016
    As our patients age, they experience metabolic changes and more frequently develop conditions such as bone mineral density loss, cardiovascular disease, diabetes, and malignancies, all of which will affect the choice of first-line ART.
  • My Approach to First-line ART for Patients With High Cardiovascular Disease Risk

    William G. Powderly MD - 10/6/2015 4 comments / Last Comment: 11/8/2015
    When treating HIV in patients with risk factors for CVD, selecting the optimal ART regimen is only part of the equation.
  • Clinical Case: Estimating Cardiovascular Disease Risk With the ASCVD Event Calculator

    David A. Wohl MD - 9/16/2015 1 comment / Last Comment: 9/17/2015
    How I used the ASCVD event calculator to estimate CVD risk for an HIV-infected patient with stably suppressed HIV-1 RNA.
  • How I Approach Patients Who Are Reluctant to Initiate ART

    Daniel R. Kuritzkes MD - 9/8/2015 4 comments / Last Comment: 6/23/2016
    In this patient case example, I review how I counsel patients who are hesitant to begin first-line ART.
  • Management of HCV/HIV Coinfection: New Data From IAS 2015

    Jürgen K. Rockstroh MD - 9/8/2015 2 comments / Last Comment: 12/12/2015
    My summary of new and noteworthy data on managing HCV/HIV coinfection from IAS 2015.
  • Adherence Concerns: Are We Limited to Boosted PIs?

    Joseph J. Eron, Jr. MD - 8/24/2015 3 comments / Last Comment: 9/3/2015
    My take on why an integrase inhibitor–based regimen makes sense for an ART-naive patient who struggles with adherence to care and medications.
  • IAS 2015: A Preview of Key Data to Be Presented in Vancouver

    Chris Beyrer MD, MPH - 7/17/2015 6 comments / Last Comment: 8/3/2015
    Here is my take on the most anticipated studies that will be presented in Vancouver this year.
10 of 86 Shown
Show 10 More
Loading...